Evidence map›Paper›PMID 38193433›Full record

ArticleJournal of investigative medicine high impact case reports

Cholestatic Drug-Induced Liver Injury in a Patient Taking High-Dose Niacin for Hyperlipidemia.

Nanjiba Nawaz, Tyler Mistretta, Christian Karime, Jason Lewis, Emily Wolf

Abstract readCase Reports
In one paragraph

Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Vitamin B3 suppressesTranslational cancer research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nanjiba NawazMayo Clinic, Jacksonville, FL, USA.ORCID 0009-0000-1749-747X
Tyler MistrettaMayo Clinic, Jacksonville, FL, USA.
Christian KarimeMayo Clinic, Jacksonville, FL, USA.
Jason LewisMayo Clinic, Jacksonville, FL, USA.
Emily WolfMayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-4849-4279

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Niacin, an important component of a balanced diet, is central to lipid metabolism. Occasionally used to treat hyperlipidemia, niacin is widely available without a prescription, making its use often unknown to treating physicians. Severe hepatotoxicity has been reported with niacin use. In the following report, we describe a case of hospitalization for acute decompensated cirrhosis with cholestatic morphology in a patient taking self-initiated large quantities of extended-release niacin. Despite medical management and support, the patient unfortunately expired on day 16 of hospitalization. Given ease of access and unclear long-term benefit in hyperlipidemia, the current case serves to raise awareness of niacin's potential hepatotoxicity through highlighting a severe outcome. Although mode of liver injury remains unknown, the use of extended-release niacin formulations and prolonged high-dose supplementation is associated with enhanced hepatotoxicity. Careful review and counseling of commonly available supplements remains an important task of both hospital and primary care physicians.

Indexed as

Chemical and Drug Induced Liver InjuryCholestasisHyperlipidemiasNiacinDietary SupplementsHumansNiacincholestaticcirrhosisdrug-inducedgastroenterologyhepatotoxicityhyperlipidemianiacin

Identifiers

PMID38193433
PMCPMC10777760

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.